# Drew Dennison

> Drew Dennison is a Series A investor at Lightchain backing Biotechnology. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Firm: [Lightchain](https://shizune.co/investors/profile/lightchain)
- Location: St Louis, United States
- Total investments: 8
- Last investment: Nov 2025
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/drew-dennison-aa711b137

Drew Dennison is a Series A investor at Lightchain in St Louis focused on Biotechnology and Health Care. Drew Dennison

## Contacts

5 contacts available for Drew Dennison: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/drew-dennison-d7b8?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $6.9M–$43M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 50% |
| Health Care | 2 | 25% |
| Health Diagnostics | 2 | 25% |
| Genetics | 1 | 13% |
| Security | 1 | 13% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 38% |
| Seed | 1 | 13% |
| Pre-Seed | 1 | 13% |
| Series B | 1 | 13% |
| Series C | 1 | 13% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 50% |
| Denmark | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AI Proteins | AI Proteins is a biotechnology company that focuses on the design and engineering of synthetic mini protein therapeutics. The company was founded in 2021 and is headquartered in Andover, Massachusetts. | $42.5M | Series A | Nov 19, 2025 | https://aiproteins.bio/ |
| Geneoscopy | Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. | $105M | Series C | Jan 08, 2025 | http://www.geneoscopy.com/ |
| Coana (acquired by Socket) | Coana helps software teams tackle the flood of alerts from traditional SCA tools. By using advanced reachability analysis, Coana cuts false alerts by over 80%, freeing up significant engineering time without sacrificing security. Coana is developed by leading program analysis researchers and is backed by Sequoia Capital and Essence VC. | $1.6M | Pre-Seed | Jan 23, 2024 | https://coana.tech |
| AI Proteins | AI Proteins is a biotechnology company that focuses on the design and engineering of synthetic mini protein therapeutics. The company was founded in 2021 and is headquartered in Andover, Massachusetts. | $18.2M | Seed | Jan 21, 2022 | https://aiproteins.bio/ |
| Geneoscopy | Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. | $105M | Series B | Nov 16, 2021 | http://www.geneoscopy.com/ |
| Mana Therapeutics | Educating Immune Cells, Eliminating Cancer. Our team of scientists, physicians, and advocates are passionate about one thing: harnessing our immune cells to combat cancer - conferring lifelong immunity to the disease. Meet the team charged with immune cell education and cancer elimination. | $35M | Series A | Jan 08, 2021 | https://www.manatherapeutics.com/ |
| Adarza BioSystems | Adarza BioSystems is an early-stage medical diagnostics company developing a rapid and label-free biological assay platform for measuring clinical and point-of-care (POC) samples. In addition to performing sophisticated clinical tests within minutes, this technology potentially allowing hundreds of tests to be run simultaneously on a single chip.It was founded in 2008 and headquartered in St Louis, Missouri. | $25M | Series D | Feb 04, 2020 | http://www.adarzabio.com |
| Geneoscopy | Geneoscopy is a non-invasive colorectal cancer diagnostic powered by advanced research in computational biology. The company is determined to replace every patient’s least favorite screen: the colonoscopy. Currently there is no test with high enough specificity and sensitivity to allow patients an alternative to the unpleasant, invasivecolonoscopy. Geneoscopy is changing that.It has developed a novel methodology to reliably and consistently extract human RNA transcripts from stool samples and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of RNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the prevention of colorectal cancer and is conducting research on other applications of its technology for tangential indications. | $6.9M | Series A | Oct 02, 2019 | http://www.geneoscopy.com/ |

8 of 8 investments shown.

## Co-investors
- [Cobro Ventures](https://shizune.co/investors/profile/cobro-ventures) — VC Fund, 3 deals together
- [Cultivation Capital](https://shizune.co/investors/profile/cultivation-capital) — VC Fund, 2 deals together
- [LabCorp](https://shizune.co/investors/profile/laboratory-corporation-of-america) — VC Fund, 2 deals together
- [Morningside](https://shizune.co/investors/profile/morningside-technology-ventures) — VC Fund, 2 deals together
- [NT Asset](https://shizune.co/investors/profile/nt-asset) — VC Fund, 2 deals together
- [NT Investments](https://shizune.co/investors/profile/nt-investments) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Accel](https://shizune.co/investors/profile/accel) — VC Fund
- [SV Angel](https://shizune.co/investors/profile/sv-angel) — VC Fund
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Vaekstfonden](https://shizune.co/investors/profile/v%C3%A6kstfonden) — VC Fund
- [PSV](https://shizune.co/investors/profile/preseed-innovation) — VC Fund
- [Seed Capital](https://shizune.co/investors/profile/seed-capital) — VC Fund

## Featured in investor lists
- [Enterprise Software Investors in Denmark](https://shizune.co/investors/enterprise-software-investors-denmark)
- [Enterprise Software Angel Investors in Denmark](https://shizune.co/investors/enterprise-software-angel-investors-denmark)

## FAQ

### What does Drew Dennison invest in?

Drew Dennison invests primarily in Biotechnology, Health Care and Health Diagnostics startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Drew Dennison's check size?

Drew Dennison typically joins rounds of $6.9M–$43M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Drew Dennison participates in.

### How do I contact Drew Dennison?

Public channels for Drew Dennison include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Drew Dennison last invest?

The most recent investment recorded for Drew Dennison closed in Nov 2025. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co